Glenmark Pharmaceuticals Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Enhanced Price Appeal

As of 18 May 2026, Glenmark Pharmaceuticals trades at ₹2,324.95, slightly below its previous close of ₹2,340.30. The stock’s 52-week range spans from ₹1,372.00 to ₹2,471.05, indicating a strong recovery and sustained upward momentum over the past year. The company’s P/E ratio currently stands at 26.82, a figure that has contributed to its upgraded valuation grade from attractive to very attractive. This P/E multiple is reasonable when compared to the broader pharmaceutical sector, where peers such as Lupin and Aurobindo Pharma trade at P/E ratios of 18.14 and 24.85 respectively, while others like Mankind Pharma and Laurus Labs command significantly higher multiples of 55.36 and 80.45.

Similarly, Glenmark’s price-to-book value of 6.83, while elevated, is justified by its strong return on equity (ROE) of 23.46% and return on capital employed (ROCE) of 44.14%. These profitability metrics underscore the company’s efficient capital utilisation and robust earnings generation capacity, which investors have rewarded with a premium valuation.

Peer Comparison Highlights Relative Attractiveness

When analysed alongside its peers, Glenmark’s valuation stands out for its balance of growth potential and reasonable pricing. For instance, Biocon and Alkem Laboratories, both rated as attractive, trade at P/E ratios of 92.6 and 27.24 respectively, with Biocon’s valuation appearing stretched relative to Glenmark’s. Conversely, companies like Laurus Labs and Anthem Biosciences are classified as very expensive, with P/E multiples exceeding 80, signalling potential overvaluation risks.

Moreover, Glenmark’s EV to EBITDA ratio of 14.65 compares favourably against Lupin’s 11.57 and Mankind Pharma’s 32.27, indicating a more balanced enterprise value relative to earnings before interest, tax, depreciation and amortisation. The company’s PEG ratio of 0.03 further emphasises its undervaluation relative to expected earnings growth, a stark contrast to peers such as Lupin (0.24) and Alkem Labs (2.45), where higher PEG ratios suggest less compelling growth-to-price dynamics.

Strong Financial Performance Supports Valuation Upgrade

Glenmark’s recent financial results have reinforced investor confidence, with the company delivering a year-to-date return of 14.20%, outperforming the Sensex’s negative 11.71% over the same period. Over the past year, Glenmark’s stock has surged by 60.77%, vastly outpacing the Sensex’s decline of 8.84%. Longer-term performance is even more impressive, with three- and five-year returns of 281.92% and 282.49% respectively, dwarfing the Sensex’s 20.68% and 54.39% gains.

This sustained outperformance is underpinned by Glenmark’s strategic focus on innovation, expanding its product pipeline, and strengthening its global footprint in key markets. The company’s dividend yield, though modest at 0.22%, complements its growth profile by signalling a commitment to shareholder returns without compromising reinvestment capacity.

Mojo Score and Rating Reflect Confidence with Slight Downgrade

MarketsMOJO assigns Glenmark Pharmaceuticals a Mojo Score of 78.0, reflecting strong fundamentals and positive market sentiment. The company’s Mojo Grade has recently been adjusted from Strong Buy to Buy as of 14 May 2026, signalling a cautious but still optimistic stance. This recalibration acknowledges the stock’s elevated valuation metrics while recognising its robust earnings growth and operational efficiency.

The mid-cap classification further emphasises Glenmark’s growth potential relative to larger pharmaceutical conglomerates, offering investors an opportunity to capitalise on expansion prospects within the sector. The slight downgrade in rating should be viewed in the context of valuation normalisation rather than deteriorating fundamentals.

Valuation Trends and Investor Implications

The transition from attractive to very attractive valuation grades is significant for investors seeking entry points in the pharmaceutical sector. Glenmark’s current P/E of 26.82 is below the sector’s average for comparable mid-cap peers, suggesting a margin of safety. Its P/BV of 6.83, while higher than some peers, is supported by superior returns on equity and capital employed, indicating that the premium is justified by quality.

Investors should also consider Glenmark’s EV to EBIT and EV to Capital Employed ratios of 16.76 and 7.89 respectively, which are consistent with efficient capital management and earnings generation. These metrics, combined with a PEG ratio near zero, highlight the company’s undervaluation relative to its growth trajectory.

Market Context and Future Outlook

Glenmark’s valuation improvement comes at a time when the pharmaceutical sector is navigating regulatory challenges, pricing pressures, and evolving global demand dynamics. The company’s ability to maintain strong profitability metrics and deliver consistent returns positions it well to weather sector headwinds.

Furthermore, Glenmark’s strategic initiatives in research and development, coupled with its expanding international presence, are expected to drive sustainable earnings growth. Investors should monitor upcoming quarterly results and pipeline developments to gauge the continuation of this positive trend.

While the stock’s recent day change of -0.66% reflects short-term volatility, the broader trend remains constructive. The company’s valuation parameters now offer a compelling entry point for investors seeking exposure to a fundamentally sound pharmaceutical player with growth visibility and reasonable pricing.

Conclusion

Glenmark Pharmaceuticals Ltd. has successfully transitioned its valuation profile from attractive to very attractive, supported by solid financial performance and favourable peer comparisons. Its P/E ratio of 26.82 and P/BV of 6.83, combined with exceptional ROCE and ROE figures, underscore the company’s operational strength and growth potential. Despite a slight downgrade in Mojo Grade from Strong Buy to Buy, the stock remains a compelling option within the mid-cap pharmaceutical space, offering investors a balanced mix of growth and value.

Given the company’s robust returns relative to the Sensex and its attractive valuation metrics, Glenmark is well positioned to capitalise on sector opportunities while delivering shareholder value over the medium to long term.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today